-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
News from March 1, 2021 //---According to a new study from Yale University, for COVID-19 patients, a new testing method can help them get rid of the risk of severe illness.
In a recent study, researchers reported that a series of biomarkers or biosignals related to white blood cell activation and obesity can predict the severe prognosis of COVID-19 patients.
In a recent study, researchers reported that a series of biomarkers or biosignals related to white blood cell activation and obesity can predict the severe prognosis of COVID-19 patients.
(Image source: Www.
pixabay.
com)
pixabay.
com)
The findings were published in the recent "Blood Advances" magazine.
"Patients with high levels of these markers have a higher risk of severe illness, require mechanical ventilation, and the mortality rate is correspondingly higher," said the first author, Dr.
Hyung Chun, associate professor of medicine.
Hyung Chun, associate professor of medicine.
Previously, some laboratory studies have identified possible indicators of severe COVID-19, including the level of D-dimer, the degree of blood clotting, and the level of proteins called cytokines, which are released as part of the inflammatory response in the body.
However, until now, no laboratory markers have been able to predict which COVID-19 patients will eventually become critically ill patients before the clinical signs and symptoms of serious diseases appear.
However, until now, no laboratory markers have been able to predict which COVID-19 patients will eventually become critically ill patients before the clinical signs and symptoms of serious diseases appear.
For this new study, researchers at Yale University used proteomic analysis (a screening of multiple proteins in the blood) to analyze samples from 100 patients who will continue to experience varying levels of COVID-19 severity.
In all cases, blood samples are collected on the first day of admission.
The researchers also analyzed the clinical data of more than 3,000 COVID-19 patients in the Yale New Haven Hospital system.
In all cases, blood samples are collected on the first day of admission.
The researchers also analyzed the clinical data of more than 3,000 COVID-19 patients in the Yale New Haven Hospital system.
They found that in COVID-19 patients who later became critically ill patients, five proteins (resistin, lipoprotein-2, HGF, IL-8 and G-CSF) related to neutrophils (a type of white blood cell) increased high.
Many of these proteins have previously been associated with obesity, but have nothing to do with COVID-19 or other viral diseases.
Many of these proteins have previously been associated with obesity, but have nothing to do with COVID-19 or other viral diseases.
It is worth noting that before those symptoms appear, the obvious neutrophil biomarkers are elevated, and these patients will continue to experience more severe symptoms.
All COVID-19 patients admitted to the hospital or transferred to the ICU have elevated neutrophil activation markers, but for patients who have never had a serious disease, these biomarkers are still at a low level.
None of the patients with low levels of neutrophil biomarkers died.
All COVID-19 patients admitted to the hospital or transferred to the ICU have elevated neutrophil activation markers, but for patients who have never had a serious disease, these biomarkers are still at a low level.
None of the patients with low levels of neutrophil biomarkers died.
The author of the study, Dr.
Alfred Lee, associate professor of hematology and medicine, said: "This is the first time that a set of biomarkers in the blood of COVID patients can even predict the situation before admission to the intensive care unit.
" Researchers say that early understanding of these indicators can significantly improve the treatment of patients.
(Bioon.
com)
Alfred Lee, associate professor of hematology and medicine, said: "This is the first time that a set of biomarkers in the blood of COVID patients can even predict the situation before admission to the intensive care unit.
" Researchers say that early understanding of these indicators can significantly improve the treatment of patients.
(Bioon.
com)
Source of information: com/news/2021-02-blood-early-indicator-severe-covid-.
html">Blood tests offer early indicator of severe COVID-19
html">Blood tests offer early indicator of severe COVID-19
Original source: Matthew L.
Meizlish et al.
org/bloodadvances/article/5/5/1164/475293/A-neutrophil-activation-signature-predicts">A neutrophil activation signature predicts critical illness and mortality in COVID-19 , Blood Advances (2021).
DOI: 10.
1182/bloodadvances.
2020003568
Meizlish et al.
org/bloodadvances/article/5/5/1164/475293/A-neutrophil-activation-signature-predicts">A neutrophil activation signature predicts critical illness and mortality in COVID-19 , Blood Advances (2021).
DOI: 10.
1182/bloodadvances.
2020003568
"Patients with high levels of these markers have a higher risk of severe illness, require mechanical ventilation, and the mortality rate is correspondingly higher," said the first author, Dr.
Hyung Chun, associate professor of medicine.
Hyung Chun, associate professor of medicine.
Previously, some laboratory studies have identified possible indicators of severe COVID-19, including the level of D-dimer, the degree of blood clotting, and the level of proteins called cytokines, which are released as part of the inflammatory response in the body.
However, until now, no laboratory markers have been able to predict which COVID-19 patients will eventually become critically ill patients before the clinical signs and symptoms of serious diseases appear.
However, until now, no laboratory markers have been able to predict which COVID-19 patients will eventually become critically ill patients before the clinical signs and symptoms of serious diseases appear.
For this new study, researchers at Yale University used proteomic analysis (a screening of multiple proteins in the blood) to analyze samples from 100 patients who will continue to experience varying levels of COVID-19 severity.
In all cases, blood samples are collected on the first day of admission.
The researchers also analyzed the clinical data of more than 3,000 COVID-19 patients in the Yale New Haven Hospital system.
In all cases, blood samples are collected on the first day of admission.
The researchers also analyzed the clinical data of more than 3,000 COVID-19 patients in the Yale New Haven Hospital system.
They found that in COVID-19 patients who later became critically ill patients, five proteins (resistin, lipoprotein-2, HGF, IL-8 and G-CSF) related to neutrophils (a type of white blood cell) increased high.
Many of these proteins have previously been associated with obesity, but have nothing to do with COVID-19 or other viral diseases.
Many of these proteins have previously been associated with obesity, but have nothing to do with COVID-19 or other viral diseases.
It is worth noting that before those symptoms appear, the obvious neutrophil biomarkers are elevated, and these patients will continue to experience more severe symptoms.
All COVID-19 patients admitted to the hospital or transferred to the ICU have elevated neutrophil activation markers, but for patients who have never had a serious disease, these biomarkers are still at a low level.
None of the patients with low levels of neutrophil biomarkers died.
All COVID-19 patients admitted to the hospital or transferred to the ICU have elevated neutrophil activation markers, but for patients who have never had a serious disease, these biomarkers are still at a low level.
None of the patients with low levels of neutrophil biomarkers died.
The author of the study, Dr.
Alfred Lee, associate professor of hematology and medicine, said: "This is the first time that a set of biomarkers in the blood of COVID patients can even predict the situation before admission to the intensive care unit.
" Researchers say that early understanding of these indicators can significantly improve the treatment of patients.
(Bioon.
com)
Alfred Lee, associate professor of hematology and medicine, said: "This is the first time that a set of biomarkers in the blood of COVID patients can even predict the situation before admission to the intensive care unit.
" Researchers say that early understanding of these indicators can significantly improve the treatment of patients.
(Bioon.
com)
Source of information: com/news/2021-02-blood-early-indicator-severe-covid-.
html">Blood tests offer early indicator of severe COVID-19
html">Blood tests offer early indicator of severe COVID-19
Original source: Matthew L.
Meizlish et al.
org/bloodadvances/article/5/5/1164/475293/A-neutrophil-activation-signature-predicts">A neutrophil activation signature predicts critical illness and mortality in COVID-19 , Blood Advances (2021).
DOI: 10.
1182/bloodadvances.
2020003568
Meizlish et al.
org/bloodadvances/article/5/5/1164/475293/A-neutrophil-activation-signature-predicts">A neutrophil activation signature predicts critical illness and mortality in COVID-19 , Blood Advances (2021).
DOI: 10.
1182/bloodadvances.
2020003568
Previously, some laboratory studies have identified possible indicators of severe COVID-19, including the level of D-dimer, the degree of blood clotting, and the level of proteins called cytokines, which are released as part of the inflammatory response in the body.
However, until now, no laboratory markers have been able to predict which COVID-19 patients will eventually become critically ill patients before the clinical signs and symptoms of serious diseases appear.
However, until now, no laboratory markers have been able to predict which COVID-19 patients will eventually become critically ill patients before the clinical signs and symptoms of serious diseases appear.
For this new study, researchers at Yale University used proteomic analysis (a screening of multiple proteins in the blood) to analyze samples from 100 patients who will continue to experience varying levels of COVID-19 severity.
In all cases, blood samples are collected on the first day of admission.
The researchers also analyzed the clinical data of more than 3,000 COVID-19 patients in the Yale New Haven Hospital system.
In all cases, blood samples are collected on the first day of admission.
The researchers also analyzed the clinical data of more than 3,000 COVID-19 patients in the Yale New Haven Hospital system.
They found that in COVID-19 patients who later became critically ill patients, five proteins (resistin, lipoprotein-2, HGF, IL-8 and G-CSF) related to neutrophils (a type of white blood cell) increased high.
Many of these proteins have previously been associated with obesity, but have nothing to do with COVID-19 or other viral diseases.
Many of these proteins have previously been associated with obesity, but have nothing to do with COVID-19 or other viral diseases.
It is worth noting that before those symptoms appear, the obvious neutrophil biomarkers are elevated, and these patients will continue to experience more severe symptoms.
All COVID-19 patients admitted to the hospital or transferred to the ICU have elevated neutrophil activation markers, but for patients who have never had a serious disease, these biomarkers are still at a low level.
None of the patients with low levels of neutrophil biomarkers died.
All COVID-19 patients admitted to the hospital or transferred to the ICU have elevated neutrophil activation markers, but for patients who have never had a serious disease, these biomarkers are still at a low level.
None of the patients with low levels of neutrophil biomarkers died.
The author of the study, Dr.
Alfred Lee, associate professor of hematology and medicine, said: "This is the first time that a set of biomarkers in the blood of COVID patients can even predict the situation before admission to the intensive care unit.
" Researchers say that early understanding of these indicators can significantly improve the treatment of patients.
(Bioon.
com)
Alfred Lee, associate professor of hematology and medicine, said: "This is the first time that a set of biomarkers in the blood of COVID patients can even predict the situation before admission to the intensive care unit.
" Researchers say that early understanding of these indicators can significantly improve the treatment of patients.
(Bioon.
com)
Source of information: com/news/2021-02-blood-early-indicator-severe-covid-.
html">Blood tests offer early indicator of severe COVID-19
html">Blood tests offer early indicator of severe COVID-19
Original source: Matthew L.
Meizlish et al.
org/bloodadvances/article/5/5/1164/475293/A-neutrophil-activation-signature-predicts">A neutrophil activation signature predicts critical illness and mortality in COVID-19 , Blood Advances (2021).
DOI: 10.
1182/bloodadvances.
2020003568
Meizlish et al.
org/bloodadvances/article/5/5/1164/475293/A-neutrophil-activation-signature-predicts">A neutrophil activation signature predicts critical illness and mortality in COVID-19 , Blood Advances (2021).
DOI: 10.
1182/bloodadvances.
2020003568
For this new study, researchers at Yale University used proteomic analysis (a screening of multiple proteins in the blood) to analyze samples from 100 patients who will continue to experience varying levels of COVID-19 severity.
In all cases, blood samples are collected on the first day of admission.
The researchers also analyzed the clinical data of more than 3,000 COVID-19 patients in the Yale New Haven Hospital system.
In all cases, blood samples are collected on the first day of admission.
The researchers also analyzed the clinical data of more than 3,000 COVID-19 patients in the Yale New Haven Hospital system.
They found that in COVID-19 patients who later became critically ill patients, five proteins (resistin, lipoprotein-2, HGF, IL-8 and G-CSF) related to neutrophils (a type of white blood cell) increased high.
Many of these proteins have previously been associated with obesity, but have nothing to do with COVID-19 or other viral diseases.
Many of these proteins have previously been associated with obesity, but have nothing to do with COVID-19 or other viral diseases.
It is worth noting that before those symptoms appear, the obvious neutrophil biomarkers are elevated, and these patients will continue to experience more severe symptoms.
All COVID-19 patients admitted to the hospital or transferred to the ICU have elevated neutrophil activation markers, but for patients who have never had a serious disease, these biomarkers are still at a low level.
None of the patients with low levels of neutrophil biomarkers died.
All COVID-19 patients admitted to the hospital or transferred to the ICU have elevated neutrophil activation markers, but for patients who have never had a serious disease, these biomarkers are still at a low level.
None of the patients with low levels of neutrophil biomarkers died.
The author of the study, Dr.
Alfred Lee, associate professor of hematology and medicine, said: "This is the first time that a set of biomarkers in the blood of COVID patients can even predict the situation before admission to the intensive care unit.
" Researchers say that early understanding of these indicators can significantly improve the treatment of patients.
(Bioon.
com)
Alfred Lee, associate professor of hematology and medicine, said: "This is the first time that a set of biomarkers in the blood of COVID patients can even predict the situation before admission to the intensive care unit.
" Researchers say that early understanding of these indicators can significantly improve the treatment of patients.
(Bioon.
com)
Source of information: com/news/2021-02-blood-early-indicator-severe-covid-.
html">Blood tests offer early indicator of severe COVID-19
html">Blood tests offer early indicator of severe COVID-19
Original source: Matthew L.
Meizlish et al.
org/bloodadvances/article/5/5/1164/475293/A-neutrophil-activation-signature-predicts">A neutrophil activation signature predicts critical illness and mortality in COVID-19 , Blood Advances (2021).
DOI: 10.
1182/bloodadvances.
2020003568
Meizlish et al.
org/bloodadvances/article/5/5/1164/475293/A-neutrophil-activation-signature-predicts">A neutrophil activation signature predicts critical illness and mortality in COVID-19 , Blood Advances (2021).
DOI: 10.
1182/bloodadvances.
2020003568
They found that in COVID-19 patients who later became critically ill patients, five proteins (resistin, lipoprotein-2, HGF, IL-8 and G-CSF) related to neutrophils (a type of white blood cell) increased high.
Many of these proteins have previously been associated with obesity, but have nothing to do with COVID-19 or other viral diseases.
Many of these proteins have previously been associated with obesity, but have nothing to do with COVID-19 or other viral diseases.
It is worth noting that before those symptoms appear, the obvious neutrophil biomarkers are elevated, and these patients will continue to experience more severe symptoms.
All COVID-19 patients admitted to the hospital or transferred to the ICU have elevated neutrophil activation markers, but for patients who have never had a serious disease, these biomarkers are still at a low level.
None of the patients with low levels of neutrophil biomarkers died.
All COVID-19 patients admitted to the hospital or transferred to the ICU have elevated neutrophil activation markers, but for patients who have never had a serious disease, these biomarkers are still at a low level.
None of the patients with low levels of neutrophil biomarkers died.
The author of the study, Dr.
Alfred Lee, associate professor of hematology and medicine, said: "This is the first time that a set of biomarkers in the blood of COVID patients can even predict the situation before admission to the intensive care unit.
" Researchers say that early understanding of these indicators can significantly improve the treatment of patients.
(Bioon.
com)
Alfred Lee, associate professor of hematology and medicine, said: "This is the first time that a set of biomarkers in the blood of COVID patients can even predict the situation before admission to the intensive care unit.
" Researchers say that early understanding of these indicators can significantly improve the treatment of patients.
(Bioon.
com)
Source of information: com/news/2021-02-blood-early-indicator-severe-covid-.
html">Blood tests offer early indicator of severe COVID-19
html">Blood tests offer early indicator of severe COVID-19
Original source: Matthew L.
Meizlish et al.
org/bloodadvances/article/5/5/1164/475293/A-neutrophil-activation-signature-predicts">A neutrophil activation signature predicts critical illness and mortality in COVID-19 , Blood Advances (2021).
DOI: 10.
1182/bloodadvances.
2020003568
Meizlish et al.
org/bloodadvances/article/5/5/1164/475293/A-neutrophil-activation-signature-predicts">A neutrophil activation signature predicts critical illness and mortality in COVID-19 , Blood Advances (2021).
DOI: 10.
1182/bloodadvances.
2020003568
It is worth noting that before those symptoms appear, the obvious neutrophil biomarkers are elevated, and these patients will continue to experience more severe symptoms.
All COVID-19 patients admitted to the hospital or transferred to the ICU have elevated neutrophil activation markers, but for patients who have never had a serious disease, these biomarkers are still at a low level.
None of the patients with low levels of neutrophil biomarkers died.
All COVID-19 patients admitted to the hospital or transferred to the ICU have elevated neutrophil activation markers, but for patients who have never had a serious disease, these biomarkers are still at a low level.
None of the patients with low levels of neutrophil biomarkers died.
The author of the study, Dr.
Alfred Lee, associate professor of hematology and medicine, said: "This is the first time that a set of biomarkers in the blood of COVID patients can even predict the situation before admission to the intensive care unit.
" Researchers say that early understanding of these indicators can significantly improve the treatment of patients.
(Bioon.
com)
Alfred Lee, associate professor of hematology and medicine, said: "This is the first time that a set of biomarkers in the blood of COVID patients can even predict the situation before admission to the intensive care unit.
" Researchers say that early understanding of these indicators can significantly improve the treatment of patients.
(Bioon.
com)
Source of information: com/news/2021-02-blood-early-indicator-severe-covid-.
html">Blood tests offer early indicator of severe COVID-19
html">Blood tests offer early indicator of severe COVID-19
Original source: Matthew L.
Meizlish et al.
org/bloodadvances/article/5/5/1164/475293/A-neutrophil-activation-signature-predicts">A neutrophil activation signature predicts critical illness and mortality in COVID-19 , Blood Advances (2021).
DOI: 10.
1182/bloodadvances.
2020003568
Meizlish et al.
org/bloodadvances/article/5/5/1164/475293/A-neutrophil-activation-signature-predicts">A neutrophil activation signature predicts critical illness and mortality in COVID-19 , Blood Advances (2021).
DOI: 10.
1182/bloodadvances.
2020003568
The author of the study, Dr.
Alfred Lee, associate professor of hematology and medicine, said: "This is the first time that a set of biomarkers in the blood of COVID patients can even predict the situation before admission to the intensive care unit.
" Researchers say that early understanding of these indicators can significantly improve the treatment of patients.
(Bioon.
com)
Alfred Lee, associate professor of hematology and medicine, said: "This is the first time that a set of biomarkers in the blood of COVID patients can even predict the situation before admission to the intensive care unit.
" Researchers say that early understanding of these indicators can significantly improve the treatment of patients.
(Bioon.
com)
Source of information: com/news/2021-02-blood-early-indicator-severe-covid-.
html">Blood tests offer early indicator of severe COVID-19
html">Blood tests offer early indicator of severe COVID-19
Original source: Matthew L.
Meizlish et al.
org/bloodadvances/article/5/5/1164/475293/A-neutrophil-activation-signature-predicts">A neutrophil activation signature predicts critical illness and mortality in COVID-19 , Blood Advances (2021).
DOI: 10.
1182/bloodadvances.
2020003568
Meizlish et al.
org/bloodadvances/article/5/5/1164/475293/A-neutrophil-activation-signature-predicts">A neutrophil activation signature predicts critical illness and mortality in COVID-19 , Blood Advances (2021).
DOI: 10.
1182/bloodadvances.
2020003568
Source of information: com/news/2021-02-blood-early-indicator-severe-covid-.
html">Blood tests offer early indicator of severe COVID-19
Source of information: com/news/2021-02-blood-early-indicator-severe-covid-. html">Blood tests offer early indicator of severe COVID-19
Original source: Matthew L.
Meizlish et al.
org/bloodadvances/article/5/5/1164/475293/A-neutrophil-activation-signature-predicts">A neutrophil activation signature predicts critical illness and mortality in COVID-19 , Blood Advances (2021).
DOI: 10.
1182/bloodadvances.
2020003568
Meizlish et al.
org/bloodadvances/article/5/5/1164/475293/A-neutrophil-activation-signature-predicts">A neutrophil activation signature predicts critical illness and mortality in COVID-19 , Blood Advances (2021).
DOI: 10.
1182/bloodadvances.
2020003568
html">Blood tests offer early indicator of severe COVID-19
Original source: Matthew L.
Meizlish et al.
org/bloodadvances/article/5/5/1164/475293/A-neutrophil-activation-signature-predicts">A neutrophil activation signature predicts critical illness and mortality in COVID-19 , Blood Advances (2021).
DOI: 10.
1182/bloodadvances.
2020003568
Meizlish et al.
org/bloodadvances/article/5/5/1164/475293/A-neutrophil-activation-signature-predicts">A neutrophil activation signature predicts critical illness and mortality in COVID-19 , Blood Advances (2021).
DOI: 10.
1182/bloodadvances.
2020003568
Original source: Matthew L.
Meizlish et al.
org/bloodadvances/article/5/5/1164/475293/A-neutrophil-activation-signature-predicts">A neutrophil activation signature predicts critical illness and mortality in COVID-19 , Blood Advances (2021).
DOI: 10.
1182/bloodadvances.
2020003568
Original source: org/bloodadvances/article/5/5/1164/475293/A-neutrophil-activation-signature-predicts">A neutrophil activation signature predicts critical illness and mortality in COVID-19 Blood AdvancesMeizlish et al.
org/bloodadvances/article/5/5/1164/475293/A-neutrophil-activation-signature-predicts">A neutrophil activation signature predicts critical illness and mortality in COVID-19 , Blood Advances (2021).
DOI: 10.
1182/bloodadvances.
2020003568
